Just over a week ago, Spark Therapeutics was riding high on positive data for its hemophilia B gene therapy. It’s now fallen back to earth after spooking…
Phase 2 data presented at ASH 2017 suggests that Roche's high expectations for its antibody-drug conjugate for non-Hodgkin lymphoma could be justified.
When payers and biopharma fight over pricing, patients with rare diseases can suffer. See how Real World Evidence and value-based contracts can help.
The clinical trial recorded one partial or complete response among the 48 evaluable patients, wiping 50% off Syros’ stock.
Bluebird Bio and Celgene’s CAR-T therapy bb2121 has pushed multiple myeloma into remission in more than half of the diseased patients treated.
An experimental PARP med bought up as part of Pfizer’s multibillion-dollar Medivation buyout performed well in a late-stage trial.
Survival in patients who received eryaspase on top of low-dose cytarabine was no longer than that for the group that just got chemotherapy alone.
Gilead has made a bolt-on acquisition of Cell Design with an eye to the future of CAR-T.
Orbimed is one of the biggest backers of life science companies in the world with $14 billion in asset management, but today its founder, Sam Isaly, has left…
SAGE-217 triggered near-immediate, fairly durable improvements in patients with major depressive disorder.
Patients with hemophilia B have seen their symptoms controlled for up to a year with a single dose of a gene therapy developed by Spark Therapeutics, almost…